ZANAMIVIR HYDRATE CAS 139110-80-8 Pneumonia Treatment Drugs
Zanamivir is a kind of anti influenza virus drug developed by biota company in Australia. It was marketed in the UK in 1999. Its trade name is Relenza. Zanamivir is a neuraminidase inhibitor. By inhibiting neuraminidase of influenza virus, it can change the aggregation and release of influenza virus in infected cells. Neuraminidase is the key enzyme of respiratory virus replication, which can break the chemical bond between sialic acid and cell surface protein, so as to separate the newly generated virus particles from the infected cells, and then infect the nearby normal cells. Inhibition of neuraminidase can prevent the virus from spreading to other cells in the respiratory tract. This product can be used to treat and prevent the spread of influenza virus in the respiratory tract, and it is very effective within 48 hours of the beginning of symptoms. This product is a dry powder inhaler, distributed in the respiratory tract after inhalation, such as nasopharynx, which can effectively inhibit neuraminidase activity. Oral administration of this product is invalid.
For the treatment of influenza A and B. Neuraminidase inhibitors. By inhibiting the neuraminidase of influenza virus, the product changes the aggregation and release of influenza virus in infected cells. It is suitable for the treatment of uncomplicated acute infection caused by influenza A or B virus in adults or adolescents over 12 years old with flu symptoms less than 2 days.
We can customize according to customer's requirement.